Targeting survivin and p53 in pediatric acute lymphoblastic leukemia

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Despite advances in treatment and outcomes for patients with pediatric acute lymphoblastic leukemia (ALL), there continue to be subsets of patients who are refractory to standard chemotherapy and hematopoietic stem cell transplant. Therefore, novel gene targets for therapy are needed to further advance treatment for this disease. RNA interference technology has identified survivin as a potential therapeutic target. Survivin, a member of the inhibitor of apoptosis (IAP) proteins and chromosome passenger complex, is expressed in hematologic malignancies and overexpressed in relapsed pediatric ALL. Our studies show that survivin is uniformly expressed at high levels in multiple pediatric ALL cell lines. Furthermore, silencing of survivin expression in pediatric ALL cell lines as well as primary leukemic blasts reduces viability of these cells. This includes cell lines derived from patients with relapsed disease featuring cytogenetic anomalies such as t(12;21), Philadelphia chromosome t(9;22), t(1;19) as well as a cell line carrying t(17;19) from a patient with de novo ALL. Furthermore, inhibition of survivin increases p53-dependent apoptosis that can be rescued by inhibition of p53. Finally, a screen of randomly selected primary patient samples confirms that survivin-specific small interfering RNA and survivin-targeted drug, YM155, effectively reduce viability of leukemic blasts.

Original languageEnglish (US)
Pages (from-to)623-632
Number of pages10
JournalLeukemia
Volume26
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pediatrics
Cell Line
Inhibitor of Apoptosis Proteins
Philadelphia Chromosome
Chromosomes, Human, Pair 9
Hematologic Neoplasms
Hematopoietic Stem Cells
RNA Interference
Cytogenetics
Genetic Therapy
Small Interfering RNA
Cell Survival
Chromosomes
Apoptosis
Technology
Transplants
Drug Therapy
Therapeutics
Pharmaceutical Preparations

Keywords

  • IAP
  • RNAi
  • targeted therapy

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Targeting survivin and p53 in pediatric acute lymphoblastic leukemia. / Tyner, Jeffrey; Jemal, A. M.; Thayer, Mathew (Matt); Druker, Brian; Chang, Bill.

In: Leukemia, Vol. 26, No. 4, 04.2012, p. 623-632.

Research output: Contribution to journalArticle

@article{cbd515bcbe734fe1a9bc3ea1ce3c8e1a,
title = "Targeting survivin and p53 in pediatric acute lymphoblastic leukemia",
abstract = "Despite advances in treatment and outcomes for patients with pediatric acute lymphoblastic leukemia (ALL), there continue to be subsets of patients who are refractory to standard chemotherapy and hematopoietic stem cell transplant. Therefore, novel gene targets for therapy are needed to further advance treatment for this disease. RNA interference technology has identified survivin as a potential therapeutic target. Survivin, a member of the inhibitor of apoptosis (IAP) proteins and chromosome passenger complex, is expressed in hematologic malignancies and overexpressed in relapsed pediatric ALL. Our studies show that survivin is uniformly expressed at high levels in multiple pediatric ALL cell lines. Furthermore, silencing of survivin expression in pediatric ALL cell lines as well as primary leukemic blasts reduces viability of these cells. This includes cell lines derived from patients with relapsed disease featuring cytogenetic anomalies such as t(12;21), Philadelphia chromosome t(9;22), t(1;19) as well as a cell line carrying t(17;19) from a patient with de novo ALL. Furthermore, inhibition of survivin increases p53-dependent apoptosis that can be rescued by inhibition of p53. Finally, a screen of randomly selected primary patient samples confirms that survivin-specific small interfering RNA and survivin-targeted drug, YM155, effectively reduce viability of leukemic blasts.",
keywords = "IAP, RNAi, targeted therapy",
author = "Jeffrey Tyner and Jemal, {A. M.} and Thayer, {Mathew (Matt)} and Brian Druker and Bill Chang",
year = "2012",
month = "4",
doi = "10.1038/leu.2011.249",
language = "English (US)",
volume = "26",
pages = "623--632",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Targeting survivin and p53 in pediatric acute lymphoblastic leukemia

AU - Tyner, Jeffrey

AU - Jemal, A. M.

AU - Thayer, Mathew (Matt)

AU - Druker, Brian

AU - Chang, Bill

PY - 2012/4

Y1 - 2012/4

N2 - Despite advances in treatment and outcomes for patients with pediatric acute lymphoblastic leukemia (ALL), there continue to be subsets of patients who are refractory to standard chemotherapy and hematopoietic stem cell transplant. Therefore, novel gene targets for therapy are needed to further advance treatment for this disease. RNA interference technology has identified survivin as a potential therapeutic target. Survivin, a member of the inhibitor of apoptosis (IAP) proteins and chromosome passenger complex, is expressed in hematologic malignancies and overexpressed in relapsed pediatric ALL. Our studies show that survivin is uniformly expressed at high levels in multiple pediatric ALL cell lines. Furthermore, silencing of survivin expression in pediatric ALL cell lines as well as primary leukemic blasts reduces viability of these cells. This includes cell lines derived from patients with relapsed disease featuring cytogenetic anomalies such as t(12;21), Philadelphia chromosome t(9;22), t(1;19) as well as a cell line carrying t(17;19) from a patient with de novo ALL. Furthermore, inhibition of survivin increases p53-dependent apoptosis that can be rescued by inhibition of p53. Finally, a screen of randomly selected primary patient samples confirms that survivin-specific small interfering RNA and survivin-targeted drug, YM155, effectively reduce viability of leukemic blasts.

AB - Despite advances in treatment and outcomes for patients with pediatric acute lymphoblastic leukemia (ALL), there continue to be subsets of patients who are refractory to standard chemotherapy and hematopoietic stem cell transplant. Therefore, novel gene targets for therapy are needed to further advance treatment for this disease. RNA interference technology has identified survivin as a potential therapeutic target. Survivin, a member of the inhibitor of apoptosis (IAP) proteins and chromosome passenger complex, is expressed in hematologic malignancies and overexpressed in relapsed pediatric ALL. Our studies show that survivin is uniformly expressed at high levels in multiple pediatric ALL cell lines. Furthermore, silencing of survivin expression in pediatric ALL cell lines as well as primary leukemic blasts reduces viability of these cells. This includes cell lines derived from patients with relapsed disease featuring cytogenetic anomalies such as t(12;21), Philadelphia chromosome t(9;22), t(1;19) as well as a cell line carrying t(17;19) from a patient with de novo ALL. Furthermore, inhibition of survivin increases p53-dependent apoptosis that can be rescued by inhibition of p53. Finally, a screen of randomly selected primary patient samples confirms that survivin-specific small interfering RNA and survivin-targeted drug, YM155, effectively reduce viability of leukemic blasts.

KW - IAP

KW - RNAi

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84859631420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859631420&partnerID=8YFLogxK

U2 - 10.1038/leu.2011.249

DO - 10.1038/leu.2011.249

M3 - Article

C2 - 21960246

AN - SCOPUS:84859631420

VL - 26

SP - 623

EP - 632

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 4

ER -